Indy Hematology Review
Avatar

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for Myeloproliferative Neoplasms

By Indy Hematology Review FEATURING Ayalew Tefferi
By Indy Hematology Review FEATURING Ayalew Tefferi
0 views
April 23, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)

What to Do When Patch Testing is Negative?

Feat. M. Montanez-Wiscovich
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
24:27
BMFcases

Experts Discuss Pros and Cons of Treatment Approaches in PV

Feat. T. Bat, A. Tefferi
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

17:05
BMFcases

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

Feat. T. Bat, A. Tefferi
06:18
Cleveland Clinic Taussig Cancer Institute

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Feat. A. Gerds
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
18:42
Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

Feat. A. Goldberg
24:48
Indy Hematology Review

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Feat. R. Rampal
08:11
Krisstina Gowin

Counseling Patients With Newly Diagnosed PV or ET

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin

New

Findings from a Phase 3 Study Evaluating a JAK Inhibitor compared to…

GSK Hematology

A. Fleischman

New

Phase 3 Trial Results Assessing Safety and Efficacy in Myelofibrosis…

GSK Hematology

H. Safah

13:38
Insights from 2024 EHA Annual Meeting

Top 5 Impactful MPN Abstracts From Summer Conferences

Feat. P. Bose
17:23
Vanderbilt University Medical Center (VUMC)

Management of MF After Ruxolitinib Failure

Feat. A. Kishtagari
08:59
Paola Guglielmelli

Real-World Data of Ruxolitinib in Myelofibrosis Including Patients W…

06:31
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Impact of Anemia on Clinical Outcomes in MF Patie…

Feat. H. Kathrin Al-Ali
06:03
Icahn School of Medicine at Mount Sinai

Strategies to Overcome Immune Dysregulation in MPNs

Feat. C. Cimen Bozkus
36:18
Icahn School of Medicine at Mount Sinai

Stem Cell Pathways, Aging, and Cancer Evolution in MPN

Feat. C. Jamieson
28:30
Icahn School of Medicine at Mount Sinai

Leveraging Dysregulated Signaling Networks for Therapeutic Benefit i…

Feat. S. Oh
26:45
Icahn School of Medicine at Mount Sinai

Targeting Mutant Calreticulin in MPN

Feat. A. Mullally
03:44
Haifa Kathrin Al-Ali

Optimizing Patient Outcomes: Early Intervention With Ruxolitinib in …

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
06:18
Cleveland Clinic Taussig Cancer Institute

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Feat. A. Gerds
12:26
David Ross

Optimizing Dosing of Ruxolitinib in MF

14:39
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepci…

Feat. K. Pettit
19:47
Monia Marchetti

CYTO-PV Study: Importance of Hematocrit Control and Early Interventi…

08:49
BMFcases

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

Feat. T. Bat, A. Tefferi
24:27
BMFcases

Experts Discuss Pros and Cons of Treatment Approaches in PV

Feat. T. Bat, A. Tefferi
17:05
BMFcases

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

Feat. T. Bat, A. Tefferi